Hematopoietic cell transplantation is a curative treatment for a variety of hematologic
diseases. Advances in transplantation technology have reduced early transplant-related …

Introduction: The increasing survival of girls and young women after cancer has led to a
rapid growth in research into assessment of ovarian function after treatment. Areas covered …

Sustained donor engraftment after allogeneic hematopoietic cell transplantation (HCT)
converts to healthy donor hemoglobin synthesis and halts disease symptoms in patients with …

Sickle cell disease (SCD) chronically damages multiple organs over the lifetime of affected
individuals. Allogeneic hematopoietic cell transplantation (allo-HCT) is the most studied …

In this review, we analyzed existing literature regarding the use of Gonadotropin-releasing
Hormone (GnRH) analogues (agonists, antagonists) as a co-treatment to chemotherapy and …

Patients with hematologic malignancies and those undergoing hematopoietic cell
transplantation (HCT) face a complex set of challenges when considering options for fertility …

Allogeneic hematopoietic cell transplantation (HCT) can halt organ damage and eliminate
symptoms in hemoglobin disorders, including sickle cell disease (SCD) and thalassemia …

Annually,~ 50,000 patients undergo hematopoietic stem cell transplantation (HCT)
worldwide with almost 22,000 of these patients receiving HCT in the United States. HCT is a …

Fertility preservation represents one important goal of cancer patients' management due to
the high impact on health and quality of life of survivors. The available preventive measures …

Objective: A systematic review and meta-analysis was conducted to investigate whether
gonadotropin-releasing hormone analogs (GnRHa) have a protective role in women treated …